Ridge Bio

Executive Summary

Ridge Bio is an AI-driven biotechnology company headquartered in Boulder, Colorado, founded in 2017. The company leverages proprietary machine learning models and massive cell-free datasets to design precision enzymes and targeted drug delivery systems. Its platform focuses on building safer and more effective therapeutics, including antibody-drug conjugates (ADCs) and novel biocatalysts. By integrating AI with synthetic biology, Ridge aims to accelerate the discovery and optimization of biologic drugs, reducing development timelines and improving clinical outcomes. The company operates as a private entity and has not disclosed funding or valuation details. Ridge's technology holds potential across multiple therapeutic areas, but its early-stage status means limited public information on specific pipeline candidates. The firm's differentiated approach using cell-free systems for iterative design cycles positions it uniquely in the AI-biotech landscape, though commercial traction remains unproven.

Upcoming Catalysts (preview)

• H2 2026Lead ADC candidate enters preclinical development60% success
• TBDPharmaceutical partnership for biocatalyst platform40% success
• Q1 2027Series B financing round announcement70% success